摘要
目的:探讨那格列奈治疗2型糖尿病的有效性及安全性。方法:采用随机、双盲双模拟、那格列奈与瑞格列奈(1∶1)平行对照,整个试验过程12周。入选4 8例患者分为:试验组(那格列奈) 2 4例和对照组(瑞格列奈) 2 4例,治疗期间主要观察餐后2h血糖(2hPG)及糖化血红蛋白(HbAlc)水平。结果:两组患者2hPG及HbAlc治疗后均较治疗前下降(P <0 .0 1) ,改善值两组间差异均无显著性(P >0 .0 5 )。结论:那格列奈能有效降低2型糖尿病患者的2hPG和HbAlc ,降糖效果好,不良反应(尤其是低血糖)少且程度较轻。
Objective:To investigate the effect and safety of nateglinide in treatment of patients with type 2 diabetes mellitus.Methods:A randomized double blind control trial was followed up for twelve weeks.Forty-eight selected cases were randomly divided into two groups in the ratio of one to one:observation group (nateglinide) and control group (repaglinide).The 2 hours plasma glucose(2hPG) and HbAlc levels of the patients were observed.Results:2hPG and HbAlc levels of the two groups decreased obviously after treatment(P<(0.01)).The decreasing levels of 2hPG and HbAlc of each group' had no obvious differences (P>0.05).Conclusions:Nateglinide is effective and safe for the treatment of type 2 diabetes mellitus with slight side effects.
出处
《蚌埠医学院学报》
CAS
2005年第3期237-239,共3页
Journal of Bengbu Medical College
关键词
2型糖尿病
那格列奈
血糖
糖化血红蛋白
diabetes mellitus,non-insulin-dependent
nateglinide
blood glucose
HbAlc
